ClinicalTrials.gg
TerminatedNCT03823378Updated Sep 16, 2021Results posted

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

A Phase 2 interventional study of Elsubrutinib and Upadacitinib in Rheumatoid Arthritis (RA), sponsored by AbbVie. Terminated at 30 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was terminated
Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.

Enrollment
16th of 19
97 · median 300
Started
2019
the only one that year
Phase 2
7 of 19
2 open now
Registered
12th of 19
by date
Lead sponsor
13 of 19
AbbVie

Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 16th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 2, and was the 12th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing upadacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This was a long-term extension (LTE) study to assess the safety, tolerability, and efficacy of ABBV-105 (elsubrutinib [ELS]) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in participants with rheumatoid arthritis (RA) who completed Study M16-063 (NCT03682705).

Read the detailed description

This was a Phase 2, double-blind, multicenter, long-term extension (LTE) study to assess the safety, tolerability, and efficacy of 3 doses of ABBV-105 (elsubrutinib [ELS] 5 mg, 20 mg, and 60 mg) and ABBV-599 (ELS 60 mg and upadacitinib [UPA] 15 mg) in adults with active rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs (bDMARDs). Participants who successfully completed treatment in the feeder Study M16-063, a Phase 2 dose exploratory study, were eligible to participate in this study. Those who met eligibility criteria and entered this study receiving ELS, ABBV-599, or UPA from Study M16-063 continued on their previously assigned treatment through termination of this study. Participants originally randomized to placebo in Study M16-063 rolled over to ABBV-599 in a blinded fashion in this study.

03

Conditions studied

  • Rheumatoid Arthritis (RA)

Keywords

  • Elsubrutinib
  • ABBV-105
  • Upadacitinib
  • ABBV-599
  • Rheumatoid Arthritis (RA)
  • Long-term extension (LTE)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has completed Study M16-063
  • Participant has not developed any laboratory or clinical discontinuation criteria as defined in the Study M16-063 protocol
  • Participant is willing and/or able to comply with procedures required in the current study protocol

Exclusion criteria

Exclusion Criteria:

  • Participant is currently enrolled or planning to enroll in another interventional clinical study while participating in this study (except the preceding study M16-063)
  • Participant requires vaccination with any during study participation, including at least 30 days after the last dose of study drug
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    ABBV-599 in M16-063/ABBV-599 in M16-763

    60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    ABBV-105 60 mg/UPA placebo

    60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    ABBV-105 20 mg/UPA placebo

    20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    ABBV-105 5 mg/UPA placebo

    5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    UPA 15 mg/ABBV-105 placebo

    15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks

    Drug: Upadacitinib · Drug: Placebo for elsubrutinib

  • Experimental
    Placebo in M16-063/ABBV-599 in M16-763

    Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763

    Drug: Elsubrutinib · Drug: Upadacitinib

Interventions

  • Elsubrutinib capsule will be administered orally.

    Also known as: ABBV-105

  • Upadacitinib tablet will be administered orally.

    Also known as: ABT-494

  • DrugPlacebo for elsubrutinib

    Placebo capsule for elsubrutinib will be administered orally.

  • DrugPlacebo for upadacitinib

    Upadacitinib placebo tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.

    Time frame: On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks

Secondary outcomes

  1. Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  2. Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.

    Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  3. Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

    The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.

    Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  4. Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063

    The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  5. Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria

    The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.

    Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  6. Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria

    The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.

    Time frame: Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  7. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response

    Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  8. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response

    Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  9. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response

    Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  10. Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063

    Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  11. Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063

    Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  12. Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063

    Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  13. Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063

    Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  14. Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063

    The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  15. Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  16. Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063

    C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

  17. Change in Morning Stiffness Severity From Baseline of Study M16-063

    Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.

    Time frame: Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763

07

Results

Posted Sep 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Started28161212209
Completed702221
Not completed21161010188
Withdrew: Adverse event220000
Withdrew: Lost to follow-up010010
Withdrew: Withdrawal by subject014201
Withdrew: Other, not specified191268177

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.

Time frame:
On or after the first dose of study drug in Study M16-763, and up to 30 days after the last dose of study drug in Study M16-763, up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Number of Participants With Adverse Events (AEs)11103573
SecondaryChange in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline indicates improvement in disease activity.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Disease Activity Score 28 C-reactive Protein (DAS28-CRP) From Baseline of Study M16-063 at Each Study Visit in Study M16-763
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-3.27 (-3.79 to -2.75)-1.98 (-2.83 to -1.12)-1.93 (-3.01 to -0.85)-2.55 (-3.50 to -1.60)-3.88 (-4.63 to -3.14)-2.87 (-4.05 to -1.68)
Week 24-3.43 (-3.90 to -2.95)-2.62 (-3.56 to -1.68)-2.02 (-3.18 to -0.86)-3.20 (-4.10 to -2.30)-4.02 (-4.62 to -3.43)-3.61 (-4.94 to -2.28)
Week 30-3.17 (-3.86 to -2.47)-2.37 (-3.71 to -1.03)-1.45 (-2.30 to -0.60)-3.30 (-4.43 to -2.17)-3.84 (-4.56 to -3.12)-4.08 (-4.73 to -3.44)
Week 36-3.45 (-4.14 to -2.77)-3.12 (-3.99 to -2.25)-1.63 (-2.37 to -0.89)-3.00 (-4.17 to -1.83)-4.15 (-5.02 to -3.29)-3.77 (-4.79 to -2.74)
Week 48-3.55 (-4.32 to -2.78)-2.77 (-4.92 to -0.62)-1.68 (-3.10 to -0.27)-3.16 (-4.49 to -1.84)-4.38 (-5.67 to -3.09)-3.86 (-4.88 to -2.85)
Week 60-4.06 (-4.88 to -3.25)-3.21 (-22.18 to 15.75)-2.55 (-6.90 to 1.79)-3.41 (-4.92 to -1.89)-4.12 (-5.43 to -2.81)-3.69 (-5.19 to -2.19)
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.

Time frame:
Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1878.3 (58.10 to 90.34)26.7 (10.90 to 51.95)44.4 (18.88 to 73.33)20.0 (5.67 to 50.98)77.8 (54.79 to 91.00)62.5 (30.57 to 86.32)
Week 2477.8 (59.24 to 89.39)53.8 (29.14 to 76.79)44.4 (18.88 to 73.33)50.0 (23.66 to 76.34)88.2 (65.66 to 96.71)85.7 (48.69 to 97.43)
Week 3078.3 (58.10 to 90.34)76.9 (49.74 to 91.82)28.6 (8.22 to 64.11)60.0 (31.27 to 83.18)87.5 (63.98 to 96.50)100 (67.56 to 100.00)
Week 3687.5 (69.00 to 95.66)87.5 (52.91 to 97.76)25.0 (4.56 to 69.94)40.0 (16.82 to 68.73)91.7 (64.61 to 98.51)100 (60.97 to 100.00)
Week 4877.8 (54.79 to 91.00)66.7 (30.00 to 90.32)50.0 (15.00 to 85.00)37.5 (13.68 to 69.43)87.5 (52.91 to 97.76)100 (60.97 to 100.00)
Week 60100 (70.09 to 100.00)50.0 (9.45 to 90.55)100 (34.24 to 100.00)60.0 (23.07 to 88.24)100 (56.55 to 100.00)75.0 (30.06 to 95.44)
SecondaryPercentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)

The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical Remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.

Time frame:
Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1856.5 (36.81 to 74.37)20.0 (7.05 to 45.19)11.1 (1.99 to 43.50)20.0 (5.67 to 50.98)77.8 (54.79 to 91.00)50.0 (21.52 to 78.48)
Week 2470.4 (51.52 to 84.15)53.8 (29.14 to 76.79)33.3 (12.06 to 64.58)30.0 (10.78 to 60.32)70.6 (46.87 to 86.72)71.4 (35.89 to 91.78)
Week 3065.2 (44.89 to 81.19)46.2 (23.21 to 70.86)0 (0.00 to 35.43)40.0 (16.82 to 68.73)87.5 (63.98 to 96.50)100 (67.56 to 100.00)
Week 3666.7 (46.71 to 82.03)62.5 (30.57 to 86.32)0 (0.00 to 48.99)20.0 (5.67 to 50.98)75.0 (46.77 to 91.11)66.7 (30.00 to 90.32)
Week 4872.2 (49.13 to 87.50)66.7 (30.00 to 90.32)0 (0.00 to 48.99)25.0 (7.15 to 59.07)62.5 (30.57 to 86.32)83.3 (43.65 to 96.99)
Week 6077.8 (45.26 to 93.68)50.0 (9.45 to 90.55)50.0 (9.45 to 90.55)0 (0.00 to 43.45)60.0 (23.07 to 88.24)75.0 (30.06 to 95.44)
SecondaryChange in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063

The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from Baseline indicates improvement in disease activity.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Clinical Disease Activity Index (CDAI) From Baseline of Study M16-063
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-33.68 (-40.72 to -26.64)-23.77 (-32.65 to -14.90)-19.16 (-28.05 to -10.26)-27.00 (-42.89 to -11.11)-36.01 (-44.11 to -27.91)-28.65 (-37.00 to -20.30)
Week 24-33.47 (-39.66 to -27.27)-27.20 (-34.18 to -20.22)-19.84 (-30.65 to -9.03)-35.59 (-45.25 to -25.93)-38.27 (-45.66 to -30.88)-32.93 (-41.70 to -24.15)
Week 30-32.07 (-40.11 to -24.03)-22.40 (-34.25 to -10.55)-16.72 (-22.28 to -11.16)-35.92 (-46.64 to -25.20)-36.86 (-46.20 to -27.52)-34.00 (-42.21 to -25.79)
Week 36-35.28 (-43.23 to -27.33)-28.86 (-36.56 to -21.16)-19.17 (-32.10 to -6.23)-33.99 (-47.10 to -20.88)-42.20 (-52.14 to -32.26)-32.92 (-41.43 to -24.40)
Week 48-36.26 (-45.44 to -27.08)-22.58 (-41.15 to -4.02)-18.87 (-36.40 to -1.33)-34.77 (-49.11 to -20.44)-45.69 (-57.45 to -33.93)-35.72 (-45.75 to -25.69)
Week 60-37.99 (-49.56 to -26.41)-29.70 (-216.48 to 157.08)-24.95 (-78.95 to 29.05)-37.20 (-56.11 to -18.29)-43.98 (-58.77 to -29.19)-34.38 (-46.14 to -22.61)
SecondaryPercentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria

The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a total CDAI score of less than or equal to 10.

Time frame:
Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1882.6 (62.86 to 93.02)40.0 (19.82 to 64.25)44.4 (18.88 to 73.33)50.0 (21.52 to 78.48)77.8 (54.79 to 91.00)62.5 (30.57 to 86.32)
Week 2488.9 (71.94 to 96.15)69.2 (42.37 to 87.32)55.6 (26.67 to 81.12)80.0 (49.02 to 94.33)88.2 (65.66 to 96.71)100 (67.56 to 100.00)
Week 3078.3 (58.10 to 90.34)76.9 (49.74 to 91.82)42.9 (15.82 to 74.95)80.0 (49.02 to 94.33)81.3 (56.99 to 93.41)100 (67.56 to 100.00)
Week 3686.4 (66.67 to 95.25)87.5 (52.91 to 97.76)75.0 (30.06 to 95.44)70.0 (39.68 to 89.22)83.3 (55.20 to 95.30)100 (60.97 to 100.00)
Week 4877.8 (54.79 to 91.00)66.7 (30.00 to 90.32)75.0 (30.06 to 95.44)62.5 (30.57 to 86.32)87.5 (52.91 to 97.76)100 (56.55 to 100.00)
Week 60100 (70.09 to 100.00)50.0 (9.45 to 90.55)100 (34.24 to 100.00)80.0 (37.55 to 96.38)80.0 (37.55 to 96.38)75.0 (30.06 to 95.44)
SecondaryPercentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria

The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a total CDAI score of less than or equal to 2.8.

Time frame:
Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1817.4 (6.98 to 37.14)13.3 (3.74 to 37.88)11.1 (1.99 to 43.50)12.5 (2.24 to 47.09)55.6 (33.72 to 75.44)25.0 (7.15 to 59.07)
Week 2429.6 (15.85 to 48.48)23.1 (8.18 to 50.26)11.1 (1.99 to 43.50)10.0 (1.79 to 40.42)58.8 (36.01 to 78.39)50.0 (21.52 to 78.48)
Week 3026.1 (12.55 to 46.47)30.8 (12.68 to 57.63)14.3 (2.57 to 51.31)30.0 (10.78 to 60.32)43.8 (23.10 to 66.82)87.5 (52.91 to 97.76)
Week 3636.4 (19.73 to 57.05)25.0 (7.15 to 59.07)25.0 (4.56 to 69.94)10.0 (1.79 to 40.42)41.7 (19.33 to 68.05)50.0 (18.76 to 81.24)
Week 4844.4 (24.56 to 66.28)33.3 (9.68 to 70.00)0 (0.00 to 48.99)12.5 (2.24 to 47.09)50.0 (21.52 to 78.48)100 (56.55 to 100.00)
Week 6033.3 (12.06 to 64.58)50.0 (9.45 to 90.55)50.0 (9.45 to 90.55)20.0 (3.62 to 62.45)60.0 (23.07 to 88.24)50.0 (15.00 to 85.00)
SecondaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response

Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 20% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 20% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1890.9 (72.19 to 97.47)80.0 (54.81 to 92.95)57.1 (25.05 to 84.18)66.7 (35.42 to 87.94)88.2 (65.66 to 96.71)75.0 (40.93 to 92.85)
Week 2496.2 (81.11 to 99.32)92.9 (68.53 to 98.73)85.7 (48.69 to 97.43)77.8 (45.26 to 93.68)93.8 (71.67 to 98.89)100 (67.56 to 100.00)
Week 3086.4 (66.67 to 95.25)69.2 (42.37 to 87.32)50.0 (18.76 to 81.24)80.0 (49.02 to 94.33)87.5 (63.98 to 96.50)100 (67.56 to 100.00)
Week 3687.0 (67.87 to 95.46)87.5 (52.91 to 97.76)66.7 (20.77 to 93.85)88.9 (56.50 to 98.01)91.7 (64.61 to 98.51)83.3 (43.65 to 96.99)
Week 4894.1 (73.02 to 98.95)83.3 (43.65 to 96.99)66.7 (20.77 to 93.85)85.7 (48.69 to 97.43)87.5 (52.91 to 97.76)100 (60.97 to 100.00)
Week 6088.9 (56.50 to 98.01)100 (34.24 to 100.00)100 (34.24 to 100.00)75.0 (30.06 to 95.44)100 (56.55 to 100.00)100 (51.01 to 100.00)
SecondaryPercentage of Participants With an American College of Rheumatology 50% (ACR50) Response

Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 50% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 50% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1868.2 (47.32 to 83.64)46.7 (24.81 to 69.88)40.0 (16.82 to 68.73)40.0 (16.82 to 68.73)70.6 (46.87 to 86.72)62.5 (30.57 to 86.32)
Week 2476.9 (57.95 to 88.97)64.3 (38.76 to 83.66)42.9 (15.82 to 74.95)66.7 (35.42 to 87.94)87.5 (63.98 to 96.50)100 (67.56 to 100.00)
Week 3063.6 (42.95 to 80.27)61.5 (35.52 to 82.29)16.7 (3.01 to 56.35)60.0 (31.27 to 83.18)87.5 (63.98 to 96.50)100 (67.56 to 100.00)
Week 3682.6 (62.86 to 93.02)62.5 (30.57 to 86.32)33.3 (6.15 to 79.23)66.7 (35.42 to 87.94)75.0 (46.77 to 91.11)66.7 (30.00 to 90.32)
Week 4882.4 (58.97 to 93.81)66.7 (30.00 to 90.32)66.7 (20.77 to 93.85)71.4 (35.89 to 91.78)87.5 (52.91 to 97.76)83.3 (43.65 to 96.99)
Week 6088.9 (56.50 to 98.01)50.0 (9.45 to 90.55)100 (34.24 to 100.00)75.0 (30.06 to 95.44)100 (56.55 to 100.00)100 (51.01 to 100.00)
SecondaryPercentage of Participants With an American College of Rheumatology 70% (ACR70) Response

Participants who met the following 3 conditions for improvement from baseline of Study M16-063 were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count from Baseline of Study M16-063 2. ≥ 70% improvement in 66-swollen joint count from Baseline of Study M16-063 and 3. ≥ 70% improvement in at least 3 of the 5 following parameters from Baseline of Study M16-063: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
percentage of participantsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 1847.8 (29.24 to 67.04)33.3 (15.18 to 58.29)20.0 (5.67 to 50.98)25.0 (8.89 to 53.23)55.6 (33.72 to 75.44)37.5 (13.68 to 69.43)
Week 2457.7 (38.95 to 74.46)42.9 (21.38 to 67.41)12.5 (2.24 to 47.09)55.6 (26.67 to 81.12)62.5 (38.64 to 81.52)87.5 (52.91 to 97.76)
Week 3063.6 (42.95 to 80.27)46.2 (23.21 to 70.86)14.3 (2.57 to 51.31)60.0 (31.27 to 83.18)68.8 (44.40 to 85.84)87.5 (52.91 to 97.76)
Week 3678.3 (58.10 to 90.34)50.0 (21.52 to 78.48)25.0 (4.56 to 69.94)44.4 (18.88 to 73.33)75.0 (46.77 to 91.11)66.7 (30.00 to 90.32)
Week 4858.8 (36.01 to 78.39)50.0 (18.76 to 81.24)25.0 (4.56 to 69.94)42.9 (15.82 to 74.95)75.0 (40.93 to 92.85)83.3 (43.65 to 96.99)
Week 6088.9 (56.50 to 98.01)50.0 (9.45 to 90.55)50.0 (9.45 to 90.55)25.0 (4.56 to 69.94)60.0 (23.07 to 88.24)75.0 (30.06 to 95.44)
SecondaryChange in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063

Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · swollen joint counts
Change in Swollen Joint Count 66 (SJC66) From Baseline of Study M16-063
swollen joint countsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-11.50 (-13.66 to -9.34)-9.88 (-14.37 to -5.38)-8.00 (-11.28 to -4.72)-13.42 (-18.40 to -8.43)-12.80 (-16.11 to -9.49)-9.78 (-13.06 to -6.50)
Week 24-11.67 (-13.85 to -9.49)-10.54 (-14.25 to -6.82)-7.67 (-10.13 to -5.21)-15.60 (-21.14 to -10.06)-13.24 (-16.48 to -9.99)-10.38 (-14.22 to -6.53)
Week 30-11.87 (-14.53 to -9.21)-7.69 (-11.64 to -3.74)-5.86 (-8.27 to -3.44)-15.50 (-21.05 to -9.95)-13.44 (-17.11 to -9.77)-10.75 (-14.61 to -6.89)
Week 36-12.38 (-14.84 to -9.91)-10.13 (-13.42 to -6.83)-7.75 (-11.73 to -3.77)-14.60 (-21.38 to -7.82)-14.25 (-18.71 to -9.79)-10.50 (-14.79 to -6.21)
Week 48-13.67 (-16.57 to -10.77)-8.00 (-16.13 to 0.13)-8.00 (-11.90 to -4.10)-15.88 (-21.34 to -10.41)-15.75 (-21.84 to -9.66)-10.67 (-15.34 to -5.99)
Week 60-14.44 (-17.73 to -11.16)-12.50 (-18.85 to -6.15)-7.50 (-39.27 to 24.27)-15.40 (-23.66 to -7.14)-13.00 (-20.80 to -5.20)-11.25 (-16.00 to -6.50)
SecondaryChange in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063

Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · tender joint counts
Change in Tender Joint Count 68 (TJC68) From Baseline of Study M16-063
tender joint countsABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-17.29 (-20.95 to -13.62)-12.69 (-18.77 to -6.61)-9.82 (-13.63 to -6.01)-14.17 (-21.70 to -6.63)-19.75 (-25.63 to -13.87)-10.67 (-16.21 to -5.12)
Week 24-17.93 (-21.84 to -14.02)-15.77 (-19.37 to -12.17)-8.11 (-10.95 to -5.28)-20.20 (-26.97 to -13.43)-20.76 (-27.39 to -14.14)-14.25 (-18.44 to -10.06)
Week 30-16.30 (-20.32 to -12.29)-9.54 (-18.16 to -0.92)-4.57 (-7.29 to -1.86)-19.80 (-27.25 to -12.35)-20.50 (-28.45 to -12.55)-14.88 (-18.60 to -11.15)
Week 36-16.42 (-20.15 to -12.68)-15.25 (-19.85 to -10.65)-8.00 (-15.46 to -0.54)-18.40 (-26.99 to -9.81)-24.92 (-33.96 to -15.88)-14.83 (-19.21 to -10.46)
Week 48-17.33 (-21.05 to -13.61)-12.33 (-23.09 to -1.58)-5.50 (-14.64 to 3.64)-18.88 (-28.63 to -9.12)-28.88 (-41.80 to -15.95)-15.00 (-20.10 to -9.90)
Week 60-19.78 (-25.14 to -14.41)-19.00 (-82.53 to 44.53)-11.50 (-81.38 to 58.38)-20.20 (-35.42 to -4.98)-26.20 (-36.90 to -15.50)-15.50 (-21.52 to -9.48)
SecondaryChange in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063

Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Participant's Assessment of Pain (Visual Analog Scale [VAS]) From Baseline of Study M16-063
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-49.68 (-62.42 to -36.94)-34.67 (-51.73 to -17.61)-25.57 (-56.51 to 5.37)-32.50 (-53.25 to -11.75)-56.17 (-72.40 to -39.93)-47.88 (-76.92 to -18.83)
Week 24-45.46 (-58.31 to -32.61)-48.36 (-60.60 to -36.11)-29.43 (-50.47 to -8.39)-42.00 (-61.74 to -22.26)-57.76 (-73.67 to -41.86)-59.38 (-80.35 to -38.40)
Week 30-48.18 (-61.90 to -34.46)-40.62 (-63.40 to -17.83)-20.00 (-48.48 to 8.48)-45.90 (-70.64 to -21.16)-53.63 (-71.19 to -36.06)-60.25 (-80.74 to -39.76)
Week 36-49.22 (-61.84 to -36.59)-47.13 (-72.05 to -22.20)-25.67 (-120.27 to 68.94)-46.70 (-63.40 to -30.00)-58.83 (-80.69 to -36.98)-54.83 (-90.68 to -18.98)
Week 48-60.06 (-72.78 to -47.34)-49.00 (-72.85 to -25.15)-35.00 (-69.15 to -0.85)-56.13 (-82.80 to -29.45)-58.75 (-82.80 to -34.70)-61.50 (-94.46 to -28.54)
Week 60-54.67 (-77.99 to -31.34)-52.00 (-522.13 to 418.13)-45.50 (-140.80 to 49.80)-58.80 (-73.74 to -43.86)-61.00 (-88.13 to -33.87)-55.00 (-100.36 to -9.64)
SecondaryChange in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063

Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Patient's Global Assessment of Disease Activity (PtGA) From Baseline of Study M16-063
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-45.18 (-58.36 to -32.00)-34.07 (-50.11 to -18.03)-28.57 (-61.69 to 4.55)-35.70 (-56.96 to -14.44)-56.56 (-72.18 to -40.93)-40.13 (-67.21 to -13.04)
Week 24-48.62 (-59.37 to -37.87)-45.93 (-60.14 to -31.72)-33.29 (-59.62 to -6.95)-45.20 (-61.30 to -29.10)-62.47 (-76.09 to -48.85)-58.13 (-74.96 to -41.29)
Week 30-46.18 (-60.77 to -31.60)-39.69 (-61.63 to -17.76)-21.40 (-57.54 to 14.74)-45.20 (-67.27 to -23.13)-56.31 (-71.70 to -40.92)-57.75 (-75.80 to -39.70)
Week 36-51.70 (-64.00 to -39.39)-48.63 (-73.95 to -23.30)-31.67 (-141.65 to 78.32)-46.20 (-64.52 to -27.88)-61.00 (-81.17 to -40.83)-53.33 (-84.24 to -22.42)
Week 48-54.24 (-69.66 to -38.81)-44.00 (-71.07 to -16.93)-38.67 (-88.62 to 11.28)-53.13 (-76.82 to -29.43)-60.75 (-84.13 to -37.37)-56.67 (-84.14 to -29.19)
Week 60-56.67 (-83.18 to -30.16)-56.00 (-462.60 to 350.60)-54.50 (-226.03 to 117.03)-54.60 (-70.61 to -38.59)-59.80 (-96.50 to -23.10)-57.00 (-87.75 to -26.25)
SecondaryChange in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063

The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Physician's Global Assessment of Disease Activity (PhGA) From Baseline of Study M16-063
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-57.22 (-65.56 to -48.87)-41.00 (-53.42 to -28.58)-33.00 (-61.23 to -4.77)-35.00 (-59.98 to -10.02)-59.06 (-69.39 to -48.72)-55.13 (-82.03 to -28.22)
Week 24-57.93 (-65.61 to -50.25)-48.36 (-60.05 to -36.66)-39.43 (-70.88 to -7.98)-50.89 (-68.36 to -33.42)-61.19 (-71.90 to -50.47)-62.38 (-77.73 to -47.02)
Week 30-55.04 (-64.27 to -45.82)-41.23 (-57.85 to -24.61)-41.80 (-60.33 to -23.27)-54.78 (-71.11 to -38.45)-56.20 (-73.22 to -39.18)-63.50 (-79.15 to -47.85)
Week 36-57.55 (-66.96 to -48.13)-53.75 (-70.49 to -37.01)-60.00 (-112.58 to -7.42)-54.78 (-73.97 to -35.58)-68.45 (-81.66 to -55.25)-65.83 (-89.60 to -42.06)
Week 48-56.39 (-71.53 to -41.24)-36.83 (-75.18 to 1.52)-56.67 (-93.29 to -20.04)-57.14 (-80.22 to -34.07)-66.13 (-82.33 to -49.92)-66.40 (-89.67 to -43.13)
Week 60-64.33 (-79.18 to -49.48)-56.00 (-437.19 to 325.19)-65.00 (-141.24 to 11.24)-61.50 (-88.83 to -34.17)-60.00 (-88.34 to -31.66)-56.75 (-87.94 to -25.56)
SecondaryChange in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Health Assessment Questionnaire Disability Index (HAQ-DI) From Baseline of Study M16-063
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-0.57 (-0.84 to -0.29)-0.49 (-0.84 to -0.14)-0.61 (-1.27 to 0.06)-0.61 (-1.04 to -0.19)-0.85 (-1.21 to -0.50)-0.47 (-0.77 to -0.17)
Week 24-0.59 (-0.81 to -0.36)-0.46 (-0.80 to -0.12)-0.57 (-1.24 to 0.09)-0.54 (-0.98 to -0.09)-0.59 (-0.94 to -0.25)-0.78 (-1.29 to -0.27)
Week 30-0.64 (-0.91 to -0.36)-0.45 (-0.93 to 0.03)-0.15 (-0.45 to 0.15)-0.51 (-0.94 to -0.09)-0.73 (-1.10 to -0.35)-0.75 (-1.17 to -0.33)
Week 36-0.67 (-0.95 to -0.38)-0.70 (-1.45 to 0.05)-0.33 (-0.81 to 0.14)-0.30 (-0.70 to 0.10)-0.51 (-0.94 to -0.09)-0.56 (-1.05 to -0.07)
Week 48-0.70 (-1.06 to -0.34)-0.63 (-1.76 to 0.51)-0.29 (-0.65 to 0.07)-0.42 (-0.90 to 0.06)-0.39 (-0.83 to 0.05)-0.71 (-1.17 to -0.25)
Week 60-0.78 (-1.22 to -0.34)-0.75 (-13.46 to 11.96)-0.31 (-4.28 to 3.66)-0.58 (-1.30 to 0.15)-0.48 (-1.77 to 0.82)-0.72 (-1.61 to 0.18)
SecondaryChange in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063

C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline indicates improvement.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · mg/L
Change in High-Sensitivity C-Reactive Protein (Hs-CRP) From Baseline of Study M16-063
mg/LABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-16.04 (-24.13 to -7.95)5.34 (-9.84 to 20.53)-0.96 (-6.20 to 4.28)-14.85 (-34.27 to 4.57)-11.48 (-16.88 to -6.07)-10.00 (-28.36 to 8.35)
Week 24-15.08 (-23.26 to -6.90)-0.20 (-15.16 to 14.76)-2.18 (-4.30 to -0.06)-15.09 (-38.53 to 8.34)-9.48 (-15.35 to -3.60)-13.16 (-32.31 to 5.99)
Week 30-16.61 (-27.35 to -5.88)-6.00 (-24.37 to 12.36)-1.66 (-4.91 to 1.59)-17.11 (-44.18 to 9.95)-9.55 (-14.24 to -4.85)-16.22 (-28.83 to -3.61)
Week 36-13.88 (-23.43 to -4.32)-12.43 (-27.58 to 2.73)-1.58 (-11.33 to 8.18)-13.61 (-34.50 to 7.28)-7.76 (-13.95 to -1.56)-18.34 (-37.30 to 0.62)
Week 48-16.41 (-28.14 to -4.69)-18.38 (-50.37 to 13.60)-5.99 (-17.43 to 5.45)-20.18 (-49.36 to 9.00)-7.22 (-14.57 to 0.14)-18.30 (-36.16 to -0.44)
Week 60-25.69 (-45.41 to -5.98)-31.46 (-288.63 to 225.71)-3.98 (-116.05 to 108.09)-25.58 (-67.98 to 16.83)-3.34 (-23.18 to 16.50)-12.47 (-33.61 to 8.67)
SecondaryChange in Morning Stiffness Severity From Baseline of Study M16-063

Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.

Time frame:
Baseline in Study M16-063, Weeks 18, 24, 30, 36, 48, and 60 in Study M16-763
Reported as:
Mean · units on a scale
Change in Morning Stiffness Severity From Baseline of Study M16-063
units on a scaleABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
Week 18-4.27 (-5.56 to -2.99)-2.27 (-3.69 to -0.84)-2.14 (-4.99 to 0.70)-3.40 (-6.02 to -0.78)-5.29 (-6.54 to -4.05)-2.38 (-4.65 to -0.10)
Week 24-4.48 (-5.52 to -3.44)-2.64 (-3.81 to -1.47)-3.29 (-5.89 to -0.69)-3.70 (-5.21 to -2.19)-4.88 (-6.43 to -3.32)-3.50 (-5.50 to -1.50)
Week 30-4.36 (-5.83 to -2.90)-2.23 (-4.28 to -0.18)-1.20 (-2.82 to 0.42)-4.20 (-5.66 to -2.74)-4.53 (-5.75 to -3.32)-3.13 (-5.55 to -0.70)
Week 36-4.43 (-5.95 to -2.92)-3.38 (-5.74 to -1.01)-1.00 (-5.30 to 3.30)-4.00 (-5.39 to -2.61)-5.55 (-6.80 to -4.29)-3.00 (-6.18 to 0.18)
Week 48-5.47 (-6.64 to -4.30)-3.33 (-6.49 to -0.17)-1.00 (-7.57 to 5.57)-4.13 (-6.67 to -1.58)-5.38 (-7.10 to -3.65)-3.67 (-6.90 to -0.44)
Week 60-4.89 (-6.54 to -3.24)-4.50 (-23.56 to 14.56)-3.00 (NA to NA)-4.40 (-6.66 to -2.14)-4.80 (-7.19 to -2.41)-3.00 (-5.25 to -0.75)

Adverse events

Collected over All-cause mortality is reported from enrollment to the end of study; median time on follow-up was ABBV-599 in M16-063/M16-763 (279 days); ABBV-105 60 mg/UPA placebo (183 days); ABBV-105 20 mg/UPA placebo (159 days); ABBV-105 5 mg/UPA placebo (337 days); UPA 15 mg/ABBV-105 placebo (229 days); and Placebo in M16-063/ABBV-599 in M16-763 (281 days). TEAEs/SAEs were collected from the first dose in M16-763 until 30 days after last dose, up to 52 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABBV-599 in M16-063/ABBV-599 in M16-7630/28 (0%)1/28 (3.6%)8/28 (28.6%)
ABBV-105 60 mg/UPA Placebo0/16 (0%)0/16 (0%)10/16 (62.5%)
ABBV-105 20 mg/UPA Placebo0/12 (0%)0/12 (0%)3/12 (25%)
ABBV-105 5 mg/UPA Placebo0/12 (0%)0/12 (0%)5/12 (41.7%)
UPA 15 mg/ABBV-105 Placebo0/20 (0%)1/20 (5%)7/20 (35%)
Placebo in M16-063/ABBV-599 in M16-7630/9 (0%)0/9 (0%)3/9 (33.3%)
Most frequent serious events
Most frequent serious events
EventABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
PERIPROSTHETIC FRACTUREInjury, poisoning and procedural complications0/280/160/120/121/200/9
LUNG ADENOCARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/280/160/120/120/200/9
Most frequent other events
Showing 10 of 37
Most frequent other events
EventABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders2/284/160/120/120/200/9
DRUG WITHDRAWAL SYNDROMEGeneral disorders0/280/160/120/120/201/9
INFLUENZA LIKE ILLNESSGeneral disorders0/280/160/120/120/201/9
URINARY TRACT INFECTIONInfections and infestations1/280/160/120/122/201/9
HYPERGLYCAEMIAMetabolism and nutrition disorders0/280/160/120/120/201/9
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/280/160/120/120/201/9
DIZZINESSNervous system disorders0/280/160/120/120/201/9
DEPRESSIONPsychiatric disorders0/280/160/120/120/201/9
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/281/160/121/121/200/9
ANAEMIABlood and lymphatic system disorders0/280/160/121/120/200/9

Baseline characteristics

Full Analysis Set: all participants who completed Study M16-063 and received at least 1 dose of assigned study drug in Study M16-763

Age, Continuous
Age, Continuous(years)ABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763Total
Mean57.5 ± 12.6458.6 ± 8.7558.5 ± 12.0754.5 ± 12.2161.7 ± 8.9959.4 ± 9.4858.5 ± 10.89
Sex: Female, Male
Sex: Female, Male(Participants)ABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763Total
Female181412818777
Male102042220
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763Total
White2715121220995
Black or African American0000000
American Indian or Alaska Native0100001
Native Hawaiian or other Pacific Islander0000000
Asian1000001
Duration of Rheumatoid Arthritis Diagnosis
Duration of Rheumatoid Arthritis Diagnosis(years)ABBV-599 in M16-063/ABBV-599 in M16-763ABBV-105 60 mg/UPA PlaceboABBV-105 20 mg/UPA PlaceboABBV-105 5 mg/UPA PlaceboUPA 15 mg/ABBV-105 PlaceboPlacebo in M16-063/ABBV-599 in M16-763Total
Mean10.024 ± 5.608714.212 ± 9.03275.435 ± 3.24589.466 ± 6.650813.571 ± 7.80869.684 ± 5.608710.778 ± 7.0861
08

Study locations

30 sites
  • Cliniques Universitaires Saint Luc /ID# 207719
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • UZ Leuven /ID# 207722
    Leuven, 3000, Belgium
  • Rheumatology Research Assoc /ID# 207769
    Edmonton, Alberta T5M 0H4, Canada
  • Manitoba Clinic /ID# 206852
    Winnipeg, Manitoba R3A 1M3, Canada
  • CIADS Research Co Ltd /ID# 206853
    Winnipeg, Manitoba R3N 0K6, Canada
  • Mount Sinai Hosp.-Toronto /ID# 206851
    Toronto, Ontario M5G 1X5, Canada
  • Dr. Latha Naik /ID# 213440
    Saskatoon, Saskatchewan S7K 3H3, Canada
  • Revmatolog s.r.o. /ID# 209941
    Jihlava 1, Jihlava 586 01, Czechia
  • Revmatologicky ustav Praha /ID# 209943
    Prague 2, Praha 2 128 00, Czechia
  • Revmatologie MUDr. Klara Sirova /ID# 209944
    Ostrava, 702 00, Czechia
  • CCR Czech a.s /ID# 209942
    Pardubice, 530 02, Czechia
  • CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 208186
    Miskolc, Borsod-Abauj-Zemplen 3529, Hungary
  • Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatokorhaz /ID# 208184
    Nyíregyháza, Szabolcs-Szatmar-Bereg 4400, Hungary
  • Revita Reumatologiai Rendelo /ID# 208187
    Budapest, 1027, Hungary
  • CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 208188
    Szekesfehervar, 8000, Hungary
  • Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 208185
    Veszprem, 8200, Hungary
  • Malopolskie Centrum Kliniczne /ID# 209902
    Cracow, Malopolskie 30-149, Poland
  • McBk Sc /Id# 212577
    Grodzisk Mazowiecki, Mazowieckie 05-825, Poland
  • NBR Polska /ID# 209904
    Warsaw, Mazowieckie 00-465, Poland
  • ClinicMed Daniluk, Nowak Sp.j. /ID# 212578
    Białystok, Podlaskie 15-879, Poland
  • Reumatika - Centrum Reumatologii NZOZ /ID# 209903
    Warsaw, 02-691, Poland
  • Hospital Universitario A Coruña - CHUAC /ID# 207732
    A Coruña, A Coruna 15006, Spain
  • Hospital Unversitario Marques de Valdecilla /ID# 207729
    Santander, Cantabria 39008, Spain
  • Hospital Regional de Malaga /ID# 207735
    Málaga, Malaga 29010, Spain
  • Hospital Clinic /ID# 207740
    Barcelona, 08036, Spain
  • Hospital Universitario Basurto /ID# 207737
    Bilbao, 48013, Spain
  • Hospital Universitario Virgen de las Nieves /ID# 209975
    Granada, 18014, Spain
  • Hospital Clinico Universitario San Carlos /ID# 207738
    Madrid, 28040, Spain
  • Hospital Universitario y Politecnico La Fe /ID# 207739
    Valencia, 46026, Spain
  • University of Oxford /ID# 210571
    Oxford, OX3 7LF, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Sep 2020, 15 months.

Results were first posted in Sep 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2019
First posted
Jan 30, 2019
StartActual
May 13, 2019
Primary completionActual
Sep 9, 2020
CompletionActual
Sep 9, 2020
Results first posted
Sep 16, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03823378
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
May 13, 2019
Primary completion
Sep 9, 2020
Completion
Sep 9, 2020
Results posted
Sep 16, 2021
Last update
Sep 16, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elsubrutinib · Upadacitinib

Start the discussion